A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats - PubMed (original) (raw)

. 2007 Mar;192(3):595-603.

doi: 10.1677/JOE-06-0045.

Affiliations

• PMID: 17332527
• DOI: 10.1677/JOE-06-0045

A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats

Yuichi Kikuchi et al. J Endocrinol. 2007 Mar.

Abstract

Fasudil, a Rho-kinase inhibitor, may improve insulin signaling. However, its long-term effect on metabolic abnormalities and its preventive effect on diabetic nephropathy are still unknown. We assessed these effects of fasudil in insulin-resistant diabetic rats, comparing them with those of an angiotensin II receptor blocker, olmesartan. Male Otsuka Long-Evans Tokushima fatty (OLETF) and Long-Evans Tokushima Otsuka, non-diabetic control, rats at 15 weeks of age were used. OLETF rats were randomized to receive a low or a high dose of fasudil or olmesartan for 25 weeks. To examine the therapeutic effects after the development of diabetes, OLETF rats at 30 weeks of age were given fasudil for 10 weeks. Administration of high-dose fasudil completely suppressed the development of diabetes, obesity, and dyslipidemia and increased serum adiponectin levels in OLETF rats. High-dose olmesartan also decreased hemoglobin A1c and increased serum adiponectin. There was a significant correlation between hemoglobin A1c and serum adiponectin or free fatty acid levels. The treatment with high-dose fasudil ameliorated proteinuria, glomerulosclerosis, renal interstitial fibrosis, and macrophage infiltration in OLETF rats. Olmesartan, even at the low dose, suppressed renal complications. The treatment with fasudil after the development of diabetes improved the metabolic abnormalities in OLETF rats, but could not suppress the progression of nephropathy. We conclude that the long-term treatment with fasudil prevents the development of diabetes, at least in part, by improving adipocyte differentiation in insulin-resistant diabetic rats. Early use of fasudil may prevent diabetic nephropathy.

PubMed Disclaimer

Similar articles

• The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats.
  Gojo A, Utsunomiya K, Taniguchi K, Yokota T, Ishizawa S, Kanazawa Y, Kurata H, Tajima N. Gojo A, et al. Eur J Pharmacol. 2007 Jul 30;568(1-3):242-7. doi: 10.1016/j.ejphar.2007.04.011. Epub 2007 Apr 20. Eur J Pharmacol. 2007. PMID: 17511984
• Mizoribine reduces renal injury and macrophage infiltration in non-insulin-dependent diabetic rats.
  Kikuchi Y, Imakiire T, Yamada M, Saigusa T, Hyodo T, Hyodo N, Suzuki S, Miura S. Kikuchi Y, et al. Nephrol Dial Transplant. 2005 Aug;20(8):1573-81. doi: 10.1093/ndt/gfh888. Epub 2005 May 19. Nephrol Dial Transplant. 2005. PMID: 15905195
• CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats.
  Koga K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M. Koga K, et al. Mol Med. 2002 Oct;8(10):591-9. Mol Med. 2002. PMID: 12477969 Free PMC article.
• Role of intrarenal angiotensin-converting enzyme in nephropathy of type II diabetic rats.
  Taniguchi M, Kim S, Zhan Y, Iwao H. Taniguchi M, et al. Hypertens Res. 2002 Mar;25(2):287-94. doi: 10.1291/hypres.25.287. Hypertens Res. 2002. PMID: 12047045
• Adiponectin: A Promising Target for the Treatment of Diabetes and Its Complications.
  Begum M, Choubey M, Tirumalasetty MB, Arbee S, Mohib MM, Wahiduzzaman M, Mamun MA, Uddin MB, Mohiuddin MS. Begum M, et al. Life (Basel). 2023 Nov 16;13(11):2213. doi: 10.3390/life13112213. Life (Basel). 2023. PMID: 38004353 Free PMC article. Review.

Cited by

• Rho-kinase inhibition ameliorates metabolic disorders through activation of AMPK pathway in mice.
  Noda K, Nakajima S, Godo S, Saito H, Ikeda S, Shimizu T, Enkhjargal B, Fukumoto Y, Tsukita S, Yamada T, Katagiri H, Shimokawa H. Noda K, et al. PLoS One. 2014 Nov 3;9(11):e110446. doi: 10.1371/journal.pone.0110446. eCollection 2014. PLoS One. 2014. PMID: 25365359 Free PMC article.
• A machine learning and network framework to discover new indications for small molecules.
  Gilvary C, Elkhader J, Madhukar N, Henchcliffe C, Goncalves MD, Elemento O. Gilvary C, et al. PLoS Comput Biol. 2020 Aug 7;16(8):e1008098. doi: 10.1371/journal.pcbi.1008098. eCollection 2020 Aug. PLoS Comput Biol. 2020. PMID: 32764756 Free PMC article.
• ROCK (RhoA/Rho Kinase) Activation in Atrial Fibrillation: Molecular Pathways and Clinical Implications.
  Proietti R, Giordani AS, Lorenzo CA. Proietti R, et al. Curr Cardiol Rev. 2023;19(3):e171122210986. doi: 10.2174/1573403X19666221117092951. Curr Cardiol Rev. 2023. PMID: 36625201 Free PMC article.
• Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity.
  Hahmann C, Schroeter T. Hahmann C, et al. Cell Mol Life Sci. 2010 Jan;67(2):171-7. doi: 10.1007/s00018-009-0189-x. Epub 2009 Nov 12. Cell Mol Life Sci. 2010. PMID: 19907920 Free PMC article. Review.
• Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage.
  Abdali NT, Yaseen AH, Said E, Ibrahim TM. Abdali NT, et al. Naunyn Schmiedebergs Arch Pharmacol. 2017 Apr;390(4):409-422. doi: 10.1007/s00210-017-1343-x. Epub 2017 Jan 18. Naunyn Schmiedebergs Arch Pharmacol. 2017. PMID: 28101628

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Sheridan PubFactory

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information